Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States
Open Access
- 1 May 2022
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (5) , 195.e1-195.e11
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb Co
This publication has 20 references indexed in Scilit:
- Recent developments in the treatment of advanced bladder cancerUrologic Oncology: Seminars and Original Investigations, 2018
- Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibitionNature Reviews Urology, 2017
- Immune Checkpoint Inhibition in Metastatic Urothelial CancerEuropean Urology, 2017
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2011
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinomaAnnals of Oncology, 2011
- Guidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiology and Drug Safety, 2008
- Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 TrialEuropean Urology, 2007
- Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladderCancer, 2006
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982